Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline Review, H2 2016

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline Review, H2 2016


  • Products Id :- GMDHC8353IDB
  • |
  • Pages: 198
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline Review, H2 2016

Summary

Global Markets Direct's, Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline Review, H2 2016', provides an overview of the Attention Deficit Hyperactivity Disorder (ADHD) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Attention Deficit Hyperactivity Disorder (ADHD)

The report reviews pipeline therapeutics for Attention Deficit Hyperactivity Disorder (ADHD) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Attention Deficit Hyperactivity Disorder (ADHD) therapeutics and enlists all their major and minor projects

The report assesses Attention Deficit Hyperactivity Disorder (ADHD) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Attention Deficit Hyperactivity Disorder (ADHD)

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Attention Deficit Hyperactivity Disorder (ADHD) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Attention Deficit Hyperactivity Disorder (ADHD) Overview 9

Therapeutics Development 10

Pipeline Products for Attention Deficit Hyperactivity Disorder (ADHD)-Overview 10

Pipeline Products for Attention Deficit Hyperactivity Disorder (ADHD)-Comparative Analysis 11

Attention Deficit Hyperactivity Disorder (ADHD)-Therapeutics under Development by Companies 12

Attention Deficit Hyperactivity Disorder (ADHD)-Therapeutics under Investigation by Universities/Institutes 16

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline Products Glance 17

Late Stage Products 17

Clinical Stage Products 18

Early Stage Products 19

Unknown Stage Products 20

Attention Deficit Hyperactivity Disorder (ADHD)-Products under Development by Companies 21

Attention Deficit Hyperactivity Disorder (ADHD)-Products under Investigation by Universities/Institutes 25

Attention Deficit Hyperactivity Disorder (ADHD)-Companies Involved in Therapeutics Development 26

Alcobra Ltd 26

Amarantus Bioscience Holdings, Inc. 27

APeT Holding BV 28

Arbor Pharmaceuticals, LLC 29

BCWorld Pharm Co. Ltd. 30

BioLite, Inc. 31

Collegium Pharmaceutical, Inc. 32

Curemark, LLC 33

DURECT Corporation 34

Egalet Corporation 35

Eli Lilly and Company 36

Ensysce Biosciences Inc. 37

H. Lundbeck A/S 38

Heptares Therapeutics Limited 39

Highland Therapeutics, Inc. 40

Integrative Research Laboratories Sweden AB 41

Intra-Cellular Therapies, Inc. 42

INVENT Pharmaceuticals, Inc. 43

KemPharm, Inc. 44

Luc Therapeutics, Inc. 45

Medgenics, Inc. 46

Merck & Co., Inc. 47

Neos Therapeutics, Inc. 48

NeuroDerm Ltd. 49

Neurovance, Inc. 50

NLS Pharma Group 51

Noven Pharmaceuticals, Inc. 52

P2D Bioscience 53

Polleo Pharma Limited 54

Reviva Pharmaceuticals Inc. 55

Shire Plc 56

Sunovion Pharmaceuticals Inc. 57

Supernus Pharmaceuticals, Inc. 58

Taisho Pharmaceutical Co., Ltd. 59

Taisho Pharmaceutical Holdings Co., Ltd. 60

TRImaran Pharma, Inc. 61

Attention Deficit Hyperactivity Disorder (ADHD)-Therapeutics Assessment 62

Assessment by Monotherapy Products 62

Assessment by Combination Products 63

Assessment by Target 64

Assessment by Mechanism of Action 67

Assessment by Route of Administration 70

Assessment by Molecule Type 72

Drug Profiles 74

(nicotine + opipramol hydrochloride)-Drug Profile 74

AR-08-Drug Profile 75

BCWPE-003-Drug Profile 76

BLI-1008-Drug Profile 77

BNC-375-Drug Profile 78

CB-8411-Drug Profile 79

centanafadine IR-Drug Profile 80

centanafadine SR-Drug Profile 81

CM-4612-Drug Profile 84

CTX-1301-Drug Profile 85

CTX-1302-Drug Profile 86

dasotraline hydrochloride-Drug Profile 87

dextroamphetamine-Drug Profile 89

dextroamphetamine MR-Drug Profile 90

edivoxetine hydrochloride-Drug Profile 92

Egalet-003-Drug Profile 94

eltoprazine-Drug Profile 95

etiguanfacine-Drug Profile 100

fasoracetam-Drug Profile 101

guanfacine hydrochloride ER-Drug Profile 103

histamine dihydrochloride-Drug Profile 105

HTL-1071-Drug Profile 106

INV-107-Drug Profile 108

INV-170-Drug Profile 109

IRL-752-Drug Profile 110

ITI-214-Drug Profile 111

KP-415 CR-Drug Profile 113

lisdexamfetamine dimesylate-Drug Profile 115

mazindol-Drug Profile 122

Metadoxine ER-Drug Profile 123

methylphenidate hydrochloride ER-Drug Profile 130

methylphenidate hydrochloride MR-Drug Profile 131

methylphenidate hydrochloride SR-Drug Profile 135

methylphenidate hydrochloride XR-Drug Profile 137

MGS-0028-Drug Profile 139

molindone hydrochloride ER-Drug Profile 140

niacinamide CR-Drug Profile 142

NLS-3-Drug Profile 143

NLS-4-Drug Profile 144

NT-0201-Drug Profile 145

P-001-Drug Profile 146

PBF-509-Drug Profile 147

PD-2005-Drug Profile 148

PD-3044-Drug Profile 149

PFR-08001-Drug Profile 150

PFR-8026-Drug Profile 151

RP-5063-Drug Profile 152

SHP-465-Drug Profile 154

Small Molecule to Block Dopamine, Norepinephrine and Serotonin Transporter for Attention Deficit Hyperactivity Disorder-Drug Profile 156

Small Molecules for Attention Deficit Hyperactivity Disorder-Drug Profile 157

Small Molecules to Agonize NMDA2D for Attention Deficit Hyperactivity Disorder-Drug Profile 158

Small Molecules to Inhibit Dopamine Transporter for Attention Deficit Hyperactivity Disorder-Drug Profile 159

Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders-Drug Profile 160

Small Molecules to Inhibit Dopamine, Serotonin, Norepinephrine Transporters for Central Nervous System Disorders-Drug Profile 161

Small Molecules to Inhibit Sodium Hydrogen Exchanger for ADHD-Drug Profile 162

Small Molecules to Modulate Choline Transporter for ADHD-Drug Profile 163

Synthetic Peptide to Antagonize D2 for ADHD-Drug Profile 164

TS-141-Drug Profile 165

Vaccine for CNS Disorders-Drug Profile 166

viloxazine hydrochloride ER-Drug Profile 167

vortioxetine hydrobromide-Drug Profile 168

VU-0238429-Drug Profile 174

Attention Deficit Hyperactivity Disorder (ADHD)-Dormant Projects 175

Attention Deficit Hyperactivity Disorder (ADHD)-Discontinued Products 180

Attention Deficit Hyperactivity Disorder (ADHD)-Product Development Milestones 181

Featured News & Press Releases 181

Appendix 193

Methodology 193

Coverage 193

Secondary Research 193

Primary Research 193

Expert Panel Validation 193

Contact Us 193

Disclaimer 194

List of Tables

Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD), H2 2016 14

Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD)-Comparative Analysis, H2 2016 15

Number of Products under Development by Companies, H2 2016 17

Number of Products under Development by Companies, H2 2016 (Contd..1) 18

Number of Products under Development by Companies, H2 2016 (Contd..2) 19

Number of Products under Investigation by Universities/Institutes, H2 2016 20

Comparative Analysis by Late Stage Development, H2 2016 21

Comparative Analysis by Clinical Stage Development, H2 2016 22

Comparative Analysis by Early Stage Development, H2 2016 23

Comparative Analysis by Unknown Stage Development, H2 2016 24

Products under Development by Companies, H2 2016 25

Products under Development by Companies, H2 2016 (Contd..1) 26

Products under Development by Companies, H2 2016 (Contd..2) 27

Products under Development by Companies, H2 2016 (Contd..3) 28

Products under Investigation by Universities/Institutes, H2 2016 29

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by Alcobra Ltd, H2 2016 30

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by Amarantus Bioscience Holdings, Inc., H2 2016 31

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by APeT Holding BV, H2 2016 32

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by Arbor Pharmaceuticals, LLC, H2 2016 33

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by BCWorld Pharm Co. Ltd., H2 2016 34

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by BioLite, Inc., H2 2016 35

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by Collegium Pharmaceutical, Inc., H2 2016 36

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by Curemark, LLC, H2 2016 37

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by DURECT Corporation, H2 2016 38

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by Egalet Corporation, H2 2016 39

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by Eli Lilly and Company, H2 2016 40

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by Ensysce Biosciences Inc., H2 2016 41

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by H. Lundbeck A/S, H2 2016 42

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by Heptares Therapeutics Limited, H2 2016 43

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by Highland Therapeutics, Inc., H2 2016 44

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by Integrative Research Laboratories Sweden AB, H2 2016 45

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by Intra-Cellular Therapies, Inc., H2 2016 46

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by INVENT Pharmaceuticals, Inc., H2 2016 47

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by KemPharm, Inc., H2 2016 48

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by Luc Therapeutics, Inc., H2 2016 49

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by Medgenics, Inc., H2 2016 50

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by Merck & Co., Inc., H2 2016 51

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by Neos Therapeutics, Inc., H2 2016 52

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by NeuroDerm Ltd., H2 2016 53

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by Neurovance, Inc., H2 2016 54

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by NLS Pharma Group, H2 2016 55

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by Noven Pharmaceuticals, Inc., H2 2016 56

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by P2D Bioscience, H2 2016 57

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by Polleo Pharma Limited, H2 2016 58

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by Reviva Pharmaceuticals Inc., H2 2016 59

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by Shire Plc, H2 2016 60

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by Sunovion Pharmaceuticals Inc., H2 2016 61

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by Supernus Pharmaceuticals, Inc., H2 2016 62

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by Taisho Pharmaceutical Co., Ltd., H2 2016 63

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by Taisho Pharmaceutical Holdings Co., Ltd., H2 2016 64

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by TRImaran Pharma, Inc., H2 2016 65

Assessment by Monotherapy Products, H2 2016 66

Assessment by Combination Products, H2 2016 67

Number of Products by Stage and Target, H2 2016 69

Number of Products by Stage and Mechanism of Action, H2 2016 72

Number of Products by Stage and Route of Administration, H2 2016 75

Number of Products by Stage and Molecule Type, H2 2016 77

Attention Deficit Hyperactivity Disorder (ADHD)-Dormant Projects, H2 2016 179

Attention Deficit Hyperactivity Disorder (ADHD)-Dormant Projects (Contd..1), H2 2016 180

Attention Deficit Hyperactivity Disorder (ADHD)-Dormant Projects (Contd..2), H2 2016 181

Attention Deficit Hyperactivity Disorder (ADHD)-Dormant Projects (Contd..3), H2 2016 182

Attention Deficit Hyperactivity Disorder (ADHD)-Dormant Projects (Contd..4), H2 2016 183

Attention Deficit Hyperactivity Disorder (ADHD)-Discontinued Products, H2 2016 184

List of Figures

Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD), H2 2016 14

Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD)-Comparative Analysis, H2 2016 15

Number of Products under Development by Companies, H2 2016 16

Number of Products under Investigation by Universities/Institutes, H2 2016 20

Comparative Analysis by Late Stage Development, H2 2016 21

Comparative Analysis by Clinical Stage Development, H2 2016 22

Comparative Analysis by Early Stage Products, H2 2016 23

Assessment by Monotherapy Products, H2 2016 66

Number of Products by Top 10 Targets, H2 2016 68

Number of Products by Stage and Top 10 Targets, H2 2016 68

Number of Products by Top 10 Mechanism of Actions, H2 2016 71

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 71

Number of Products by Routes of Administration, H2 2016 74

Number of Products by Stage and Routes of Administration, H2 2016 74

Number of Products by Molecule Types, H2 2016 76

Number of Products by Stage and Molecule Types, H2 2016 76

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Alcobra Ltd

Amarantus Bioscience Holdings, Inc.

APeT Holding BV

Arbor Pharmaceuticals, LLC

BCWorld Pharm Co. Ltd.

BioLite, Inc.

Collegium Pharmaceutical, Inc.

Curemark, LLC

DURECT Corporation

Egalet Corporation

Eli Lilly and Company

Ensysce Biosciences Inc.

H. Lundbeck A/S

Heptares Therapeutics Limited

Highland Therapeutics, Inc.

Integrative Research Laboratories Sweden AB

Intra-Cellular Therapies, Inc.

INVENT Pharmaceuticals, Inc.

KemPharm, Inc.

Luc Therapeutics, Inc.

Medgenics, Inc.

Merck & Co., Inc.

Neos Therapeutics, Inc.

NeuroDerm Ltd.

Neurovance, Inc.

NLS Pharma Group

Noven Pharmaceuticals, Inc.

P2D Bioscience

Polleo Pharma Limited

Reviva Pharmaceuticals Inc.

Shire Plc

Sunovion Pharmaceuticals Inc.

Supernus Pharmaceuticals, Inc.

Taisho Pharmaceutical Co., Ltd.

Taisho Pharmaceutical Holdings Co., Ltd.

TRImaran Pharma, Inc.

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutic Products under Development, Key Players in Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, Attention Deficit Hyperactivity Disorder (ADHD) Pipeline Overview, Attention Deficit Hyperactivity Disorder (ADHD) Pipeline, Attention Deficit Hyperactivity Disorder (ADHD) Pipeline Assessment

select a license
Single User License
USD 2000 INR 143840
Site License
USD 4000 INR 287680
Corporate User License
USD 6000 INR 431520

NEWSLETTER BY CATEGORY




Testimonials

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com